Showing results (291-300 of 525) with videos related to
Sort By:
Pageof 53
Wiener Klinische Wochenschrift|November 25, 1983
[Immunohistochemical detection of prostaglandins using immunoperoxidase (PAP) exemplified by a human tumor tissue]W Ulrich, M Matejka, H Porteder, et al.The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|October 18, 2006
Modification of low-density lipoprotein during radiolabeling with 99mTc using three labeling methodsG Sobal, U Resch, F Tatzber, et al.Wiener Klinische Wochenschrift|March 29, 1985
[Defects in the prostaglandin system. II. Familial platelet-prostacyclin receptor defect (Wien-Hietzing defect)--pathogenetic significance for (early) development of atherosclerosis?]J Kaliman, H Sinzinger, M Staudacher, et al.American Journal of Hematology|February 1, 1990
Prevalence of a shortened prostacyclin half-life in plasma in healthy adults: results of a screening investigationH Sinzinger, F Rauscha, P Fitscha, et al.Wiener Klinische Wochenschrift|August 13, 1976
[Bilirubin metabolism (author's transl)]H Seyfried, M Klicpera, C Leithner, et al.Wiener Klinische Wochenschrift|February 17, 1984
[Efficacy and tolerance of hepatitis B vaccination in medical personnel and hemodialysis patients]W Horak, C Leithner, W Kemenesi, et al.Wiener Medizinische Wochenschrift (1946)|July 17, 1999
[Prevention of coronary heart diseases in clinical practice. Comment on the recommendations of the Second Joint Task Force of European Societies for Prevention of Coronary Disease]W Klein, G Maurer, J R Patsch, et al.Wiener Klinische Wochenschrift|April 14, 1989
[Effects of omega-3-fatty acids on the prostaglandin system in healthy probands]A Gazsó, J Kaliman, D F Horrobin, et al.Wiener Klinische Wochenschrift|February 5, 1988
[Technic and clinical use of radioactive labelling of autologous granulocytes]E Strobl-Jäger, H Kolbe, H Ludwig, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 3, 1999
Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidationH Kritz, A Oguogho, A A Aghajanian, et al.Pageof 53